New York State Common Retirement Fund Grows Stock Holdings in Hologic, Inc. $HOLX

New York State Common Retirement Fund boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 16.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 142,622 shares of the medical equipment provider’s stock after purchasing an additional 20,000 shares during the period. New York State Common Retirement Fund owned about 0.06% of Hologic worth $9,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC purchased a new stake in shares of Hologic during the second quarter worth $26,000. Caitong International Asset Management Co. Ltd boosted its position in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares during the last quarter. Root Financial Partners LLC acquired a new position in Hologic during the third quarter worth about $27,000. SJS Investment Consulting Inc. grew its stake in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P acquired a new stake in Hologic in the 2nd quarter valued at about $33,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on HOLX. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Mizuho cut Hologic from an “outperform” rating to a “neutral” rating and upped their target price for the company from $70.00 to $78.00 in a report on Thursday, October 23rd. Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Leerink Partners boosted their price target on shares of Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday, October 21st. Finally, Needham & Company LLC restated a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Stock Down 0.1%

NASDAQ:HOLX opened at $74.63 on Wednesday. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.36. The stock’s fifty day moving average is $74.88 and its two-hundred day moving average is $71.11. The stock has a market capitalization of $16.66 billion, a price-to-earnings ratio of 31.10, a price-to-earnings-growth ratio of 2.22 and a beta of 0.72. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business’s revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.87 earnings per share. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.